Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen.
The immunogenicity and protective efficacy of a DNA and recombinant modified vaccinia Ankara (MVA) vaccine administered by two different routes were investigated. DNA expressing HIV-1 IIIB env, gag, RT, rev, tat and nef, and MVA expressing HIV-1 IIIB nef, tat and rev and simian immunodeficiency virus (SIV) macJ5 gag/pol and vaccinia HIV-1 env, were used as immunogens. Four cynomolgus macaques received DNA intramuscularly (i.m.) at month 0 and intrarectally (i.r.) and intra-orally (i.o.) at 2 months, followed by MVA i.m. at 4 months and i.r. and i.o. at 8 months. Another group of four monkeys received the same immunogens but only i.m. Overall, stronger cellular immune responses measured by ELISPOT and T-cell proliferation assay were detected in the group primed i.m. and boosted mucosally. Following homologous intravenous simian-human immunodeficiency virus (SHIV) challenge, one of eight vaccinated animals was completely protected. This monkey, immunized i.m. and i.r.+i.o., exhibited the highest levels of HIV Env, Nef and Tat antibodies, high HIV Tat cytotoxic T-lymphocyte activity and T-lymphocyte proliferative responses to HIV Env. Four weeks post-challenge none of the monkeys immunized i.m. and i.r.+i.o., and only two out of four animals immunized i.m., demonstrated detectable plasma viral RNA levels. In contrast, all eight control animals had demonstrable plasma viral RNA levels 4 weeks post-challenge. Thus, stronger cellular immune responses and reduction of challenge virus burden were demonstrated in animals immunized i.m. as well as mucosally, compared with animals immunized i.m. only. The breadth and magnitude of the induced immune responses correlated with protective efficacy.
Microbiology and Tumor Biology Center, Karolinska Institute, Sweden.|Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
B
B
Mäkitalo
Institute of Odontology, Karolinska Institute, Huddinge, Sweden.
P
P
Lundholm
Microbiology and Tumor Biology Center, Karolinska Institute, Sweden.
J
J
Hinkula
Microbiology and Tumor Biology Center, Karolinska Institute, Sweden.|Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
C
C
Nilsson
Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
K
K
Karlén
Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
A
A
Mörner
Institute of Molecular Virology, GSF-National Research Center for Environment and Health, Muenchen, Germany.
G
G
Sutter
Institute of Molecular Virology, GSF-National Research Center for Environment and Health, Muenchen, Germany.
V
V
Erfle
Department of Virology, Biomedical Primate Research Centre, Rijswijk, the Netherlands.
J L
JL
Heeney
Microbiology and Tumor Biology Center, Karolinska Institute, Sweden.|Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
B
B
Wahren
Microbiology and Tumor Biology Center, Karolinska Institute, Sweden.|Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
G
G
Biberfeld
Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden.
R
R
Thorstensson
D000818:Animals; D015483:HIV Antibodies / Q000097:blood; D007114:Immunization; D007371:Interferon-gamma / Q000096:biosynthesis; D008252:Macaca fascicularis; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology*; D014616:Vaccinia virus / Q000276:immunology*; D019562:Viral Load
D015483:HIV Antibodies; D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D007371:Interferon-gamma